

biotechne®

Asuragen®

Bringing Exosome-Powered, High-Sensitivity *ESR1* Mutation Testing to qPCR

Quantidex®


qPCR *ESR1* exoMutation Kit[†]

ExoLution™ Plus cfDNA + exoRNA Isolation Kit*

The Quantidex® qPCR *ESR1* exoMutation Kit[†] is the first multi-analyte liquid biopsy assay tailored for detecting *ESR1* mutations. Designed to provide highly sensitive detection in 11 of the most prevalent *ESR1* variants in plasma, the kit offers a novel approach to achieving more meaningful breast cancer insights.

Streamlining cfDNA + exoRNA Co-Isolation

The Quantidex qPCR *ESR1* exoMutation Kit is paired with the ExoLution™ Plus cfDNA + exoRNA Isolation Kit, leveraging proprietary chemistries to co-isolate cfDNA + exoRNA in a single workflow. ExoLution Plus includes all necessary reagents and consumables for high-quality, multi-analyte isolation to power downstream mutation detection.



Interested in becoming an Early Access Site?

Contact Us → aus.orders@bio-techne.com

Figure 1: Combined Workflow for the Quantidex qPCR *ESR1* exoMutation Kit and ExoLution Plus cfDNA and exoRNA Isolation Kit.

Bio-Techne® | R&D Systems™ Novus Biologicals™ Tocris Bioscience™ ProteinSimple™ ACD™ ExosomeDx™ Asuragen®

*For research use only. Not for use in diagnostic procedures.

[†]This product is under development; performance characteristics and final product features to be determined.

1. Breast Cancer Res. 2021 Aug 15;23(1):85. 2. Lancet Oncol. 2022 Nov;23(11):1367-1377.

3000-105 02/23
6031828679_ASU_FL_ESR1-Product-Update_TA